STRO earnings analysis
What we found in STRO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Sutro reported Q2 2026 revenue of $9.839 million and diluted EPS of negative $2.33. Revenue declined 34.4% sequentially and 84.6% year over year, while EPS improved sequentially but worsened year over year; results also included an $18.422 million restructuring charge. Liquidity increased to $164.3 million from $141.4 million at year-end, but the company remains loss-making, has an accumulated deficit of $1,055.0 million and expects to require additional funding. Pipeline milestones for STRO-006 and the Astellas program are constructive, but novel-platform, clinical, manufacturing and financing risks dominate the outlook.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue declined sequentially and year over year
- Revenue was $9.839 million, down 34.4% from $15.0 million in Q1 2026 and down 84.6% from $64.0 million in Q2 2025, reflecting the volatility of collaboration-driven revenue.
- EPS improved sequentially, worsened year over year
- Diluted EPS was negative $2.33, an improvement of $0.61 from negative $2.94 in Q1 2026, but a deterioration of $0.93 from negative $1.40 in Q2 2025.
- Liquidity increased from year-end
- Cash, cash equivalents and marketable securities increased to $164.3 million at June 30, 2026 from $141.4 million at December 31, 2025, an increase of $22.9 million or 16.2%.
- Restructuring supports lower spending
- The quarter included an $18.422 million restructuring charge, while management reported that operating expenses declined year over year.
- Pipeline milestones remain on track
- Management expects STRO-006 to enter Phase 1 in Q3 2026 and the second Astellas program to enter the clinic by year-end 2026, providing defined pipeline milestones despite the absence of commercial products.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective at a reasonable assurance level as of June 30, 2026, and reported no changes that materially affected, or were reasonably likely to materially affect, internal control over financial reporting during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued losses require additional capital
- The company had $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, but reported a net loss of $77.0 million for the six months ended June 30, 2026 and states that it will require additional funding. Financing may cause dilution or require the company to relinquish product or technology rights.
- No approved product and large deficit
- Sutro had an accumulated deficit of $1,055.0 million as of June 30, 2026 and has no products approved for commercial sale. The filing states that commercial product revenue is not expected for the foreseeable future and that net losses may increase substantially as development progresses.
- Novel platform and manufacturing risk
- The filing emphasizes heightened development and manufacturing uncertainty for novel dual-payload ADCs and cell-free platforms, including STRO-004, STRO-006 and STRO-227. It states that no product developed on a cell-free manufacturing platform has received FDA approval, increasing regulatory, scale-up and supply-chain risk.
- AI-enabled cybersecurity threats expanded
- The risk-factor discussion expands cybersecurity exposure to AI-enabled attacks, including deepfake-enabled fraud, credential theft and ransomware. The company also states that it has experienced and may experience delays in deploying remedial measures, creating potential risks to clinical, manufacturing and confidential-data operations.
- Third-party and geopolitical supply risk
- The company relies on third-party contract manufacturers following its March 2025 and September 2025 restructurings and notes that certain raw and intermediate materials are sourced from a sole supplier. Tariffs, trade restrictions and the ongoing conflict in Iran could disrupt supply or increase costs.
- Potential third-party IP constraint
- The filing identifies an issued third-party patent relating to strained alkyne reagents that is expected to expire in 2031 and could be relevant to certain linker-payloads. Failure to obtain a license could delay commercialization of STRO-004, STRO-006 or STRO-227.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-2.33
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management indicated that $164.3 million of cash, cash equivalents and marketable securities is expected to fund operations through at least Q2 2028; STRO-006 is expected to enter Phase 1 in Q3 2026 and a second Astellas program is expected to enter the clinic by year-end 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 14, 2026
- Sutro Biopharma reported Q1 2026 revenue of $14.5 million, a 17% decrease from $17.4 million in Q1 2025, and a loss from operations of $29.7 million, significantly improved from the previous year's loss of $68.5…
- 10-K · March 23, 2026
- Sutro Biopharma is a clinical-stage oncology company advancing homogeneous and next-generation ADCs enabled by its XpressCF®/XpressCF+® cell-free platforms. The company filed and received IND clearance for STRO-004 in…
- 10-Q · November 6, 2025
- Sutro reported Q3 2025 revenue of $9.693M (three months ended Sept. 30, 2025), up from $8.520M year-over-year, while GAAP net loss widened to $56.857M (loss per share $0.67). Operating expenses fell (R&D down to…
- 10-Q · May 8, 2025
- Sutro reported revenue of $17,399 (thousands) in Q1 2025, up from $13,008 (thousands) in Q1 2024, and posted a net loss of $75,968 (thousands) or $(0.91) per share. Management completed a March 13, 2025 restructuring…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing STRO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever